These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 2497954)

  • 21. Status of a group B Neisseria meningitidis vaccine.
    Frasch CE
    Eur J Clin Microbiol; 1985 Dec; 4(6):533-6. PubMed ID: 3937731
    [No Abstract]   [Full Text] [Related]  

  • 22. Induction of endotoxin tolerance by pathogenic Neisseria is correlated with the inflammatory potential of lipooligosaccharides and regulated by microRNA-146a.
    Liu M; John CM; Jarvis GA
    J Immunol; 2014 Feb; 192(4):1768-77. PubMed ID: 24442429
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Defences against meningococcal infections.
    Lancet; 1985 Oct; 2(8461):929-30. PubMed ID: 2865427
    [No Abstract]   [Full Text] [Related]  

  • 24. Standardisation and validation of serological assays for the evaluation of immune responses to Neisseria meningitidis serogroup A and C vaccines.
    Jodar L; Cartwright K; Feavers IM
    Biologicals; 2000 Sep; 28(3):193-7. PubMed ID: 10964447
    [No Abstract]   [Full Text] [Related]  

  • 25. Recurrent meningococcal meningitis due to partial complement defects and poor anti-meningococcal antibody response.
    Herva E; Leinonen M; Käyhty H; Mäkelä PH; Vetoniemi-Korhonen SL
    J Infect; 1983 Jan; 6(1):55-60. PubMed ID: 6411822
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunogenicity of O-acetyl-negative and -positive polysaccharide vaccines for infections with Neisseria meningitidis group C in infants.
    Pichichero M; Anderson P; Gotschlich E; Kamm J; McMullen A; Nielsen S
    J Infect Dis; 1985 Oct; 152(4):850-1. PubMed ID: 3930623
    [No Abstract]   [Full Text] [Related]  

  • 27. Meningococcal meningitis.
    Lancet; 1989 Mar; 1(8639):647-8. PubMed ID: 2564462
    [No Abstract]   [Full Text] [Related]  

  • 28. [Anti-meningococcal vaccine: myth and reality].
    Nassif X
    Arch Pediatr; 1999; 6 Suppl 3():647s-649s. PubMed ID: 10429807
    [No Abstract]   [Full Text] [Related]  

  • 29. [Immune response to anti-meningococcal vaccines].
    Milagres LG; Melles CE
    Rev Saude Publica; 1993 Jun; 27(3):221-6. PubMed ID: 8115838
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cross-reactivity of Neisseria gonorrhoeae and Neisseria meningitidis and the nature of antigens involved in the bactericidal reaction.
    Tramont EC; Sadoff JC; Artenstein MS
    J Infect Dis; 1974 Sep; 130(3):240-7. PubMed ID: 4213017
    [No Abstract]   [Full Text] [Related]  

  • 31. Cellular immune responses during gonococcal and meningococcal infections.
    Cooper MD; Moticka EJ
    Clin Microbiol Rev; 1989 Apr; 2 Suppl(Suppl):S29-34. PubMed ID: 2497960
    [No Abstract]   [Full Text] [Related]  

  • 32. [Meningococcal meningitis: bacterial virulence, antibodies or complement?].
    Pujadas Capmany R; Jané Pesquer J
    Med Clin (Barc); 1984 Nov; 83(16):671-3. PubMed ID: 6439961
    [No Abstract]   [Full Text] [Related]  

  • 33. Neisseria meningitidis: vaccines and vaccine candidates.
    Al'Aldeen AA; Cartwright KA
    J Infect; 1996 Nov; 33(3):153-7. PubMed ID: 8945702
    [No Abstract]   [Full Text] [Related]  

  • 34. α-2,3-sialyltransferase expression level impacts the kinetics of lipooligosaccharide sialylation, complement resistance, and the ability of Neisseria gonorrhoeae to colonize the murine genital tract.
    Lewis LA; Gulati S; Burrowes E; Zheng B; Ram S; Rice PA
    mBio; 2015 Feb; 6(1):. PubMed ID: 25650401
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness of BC meningococcal vaccine in Brazil.
    Nishioka S
    Int J Epidemiol; 1996 Oct; 25(5):1102-3. PubMed ID: 8921501
    [No Abstract]   [Full Text] [Related]  

  • 36. [The outer membrane proteins of Neisseria meningitidis: the outlook for their use in developing preparations for immunoprophylaxis].
    Filatova TN
    Zh Mikrobiol Epidemiol Immunobiol; 1990 Feb; (2):86-95. PubMed ID: 2111623
    [No Abstract]   [Full Text] [Related]  

  • 37. [New vaccines against group B meningococcal diseases].
    Hietalahti J; Meri S
    Duodecim; 2015; 131(6):525-32. PubMed ID: 26237895
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Susceptibility to meningococcal meningitis.
    Sabath LD; Rosner B
    N Engl J Med; 1973 May; 288(22):1185. PubMed ID: 4633552
    [No Abstract]   [Full Text] [Related]  

  • 39. [The anticomplement activity of Neisseria gonorrhoeae].
    Akhunova NR; Deriabin DG; Brudastov IuA; Zhurlov OS
    Zh Mikrobiol Epidemiol Immunobiol; 1997; (4):63-7. PubMed ID: 9341004
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of complement in anti-bacterial defence.
    D'Amelio R; Biselli R
    Ann Ital Med Int; 1994; 9(3):173-7. PubMed ID: 7946895
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.